Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin

Hiroharu Oki, Mika K. Kaneko, Satoshi Ogasawara, Yuta Tsujimoto, Xing Liu, Masato Sugawara, Yuya Takakubo, Michiaki Takagi, Yukinari Kato

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)


Podoplanin (PDPN/Aggrus/T1α), a platelet aggregation-inducing type I transmembrane sialoglycoprotein, is involved in tumor invasion and metastasis. Furthermore, podoplanin expression was reported to be involved in poor prognosis of several cancers. Although many anti-podoplanin monoclonal antibodies (MAbs), such as NZ-1 and D2-40, have been established, those epitopes are limited to platelet aggregation-stimulating (PLAG) domain of podoplanin. In this study, we developed and characterized a novel anti-podoplanin MAb, LpMab-7, that is more sensitive than NZ-1 in immunohistochemistry. We identified the minimum epitope of LpMab-7 as Arg79-Leu83 of human podoplanin, which is different from PLAG domain, using ELISA, Western blot analysis, and flow cytometry. Because LpMab-7 has high sensitivity against podoplanin, LpMab-7 is expected to be useful for molecular targeting therapy for podoplanin-expressing cancers.

Original languageEnglish
Pages (from-to)174-180
Number of pages7
JournalMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
Issue number3
Publication statusPublished - 2015 Jun 1


Dive into the research topics of 'Characterization of Monoclonal Antibody LpMab-7 Recognizing Non-PLAG Domain of Podoplanin'. Together they form a unique fingerprint.

Cite this